Sutro Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Sutro Biopharma şirketinin toplam hissedar öz sermayesi $111.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $451.8M ve $340.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$388.25m
Eşitlik	US$111.22m
Toplam yükümlülükler	US$340.61m
Toplam varlıklar	US$451.83m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: S09 'nin kısa vadeli varlıkları ( $405.8M ) kısa vadeli yükümlülüklerini ( $131.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: S09 şirketinin kısa vadeli varlıkları ( $405.8M ) uzun vadeli yükümlülüklerini ( $209.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: S09 borçsuzdur.

Borcun Azaltılması: S09 şirketinin 5 yıl önce borç/öz sermaye oranı 10.3% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: S09 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: S09 serbest nakit akışı her yıl % 21.9 1.7 yıl yetecek nakit akışına sahip olacaktır.

Sutro Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$0.59 loss per share (vs US$0.81 loss in 3Q 2023)

Sutro Biopharma, Inc. Announces Initiation of the Registration-Enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-Term Pipeline At Research Forum

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO2024

Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Second quarter 2024 earnings released: US$0.59 loss per share (vs US$0.64 loss in 2Q 2023)

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

First quarter 2024 earnings released: US$0.95 loss per share (vs US$0.85 loss in 1Q 2023)

Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2024

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $74.999998 million.

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $74.999998 million.

Full year 2023 earnings released: US$1.78 loss per share (vs US$2.35 loss in FY 2022)

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC

Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.37 loss in 3Q 2022)

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023

Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer

Chief Business Officer recently sold €67k worth of stock

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.55 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.85 loss per share (vs US$0.84 loss in 1Q 2022)

Full year 2022 earnings released: US$2.35 loss per share (vs US$2.29 loss in FY 2021)

Sutro Biopharma, Inc. Announces Results from Phase 1 Dose-Expansion Study of STRO-002

Sutro Biopharma, Inc. Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.67 loss in 3Q 2021)

Sutro Biopharma, Inc. Announces Departure of Arturo Molina as Chief Medical Officer

Second quarter 2022 earnings released: US$0.55 loss per share (vs US$0.13 loss in 2Q 2021)

High number of new directors

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Growth Index

High number of new directors

First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.66 loss in 1Q 2021)

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2022

Sutro Biopharma, Inc. Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

CEO & Director recently bought €71k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

High number of new directors

Sutro Biopharma, Inc. Announces Company Kol Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program Stro-002 for Treatment of Advanced Ovarian Cancer

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present At American Society of Hematology Annual Meeting 2021

Third quarter 2021 earnings released: US$0.67 loss per share (vs US$0.47 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$1.00 profit in 2Q 2020)

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to Be Presented At ASCO 2021

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$6.61 loss per share (vs US$0.84 loss in 1Q 2020)

Full year 2020 earnings released: US$0.99 loss per share (vs US$2.43 loss in FY 2019)

Investor sentiment deteriorated over the past week

Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

New 90-day high: €21.00

Investor sentiment improved over the past week

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

Market bids up stock over the past week

New 90-day high: €18.60

Sutro Biopharma Announces Appointment of Jon M. Wigginton to Board of Directors

Sutro Biopharma, Inc. Appoints Annie Chang as Head of Investor Relations

New 90-day high: €14.30

Market bids up stock over the past week

Revenue beats expectations

Third quarter 2020 earnings released: EPS US$0.46

New 90-day high: €11.10

New 90-day high - €10.00

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin